Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes

NEWTOWN, Pa., May 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced one oral and one poster presentation at the 14^th International Symposium on Myelodysplastic Syndromes taking place May 3-6, 2017 at the Palacios de Congresos de Valencia in Valencia, Spain.  These presentations will be made by the Company's collaborators from the Mount Sinai School of Medicine and the Cleveland Clinic.

Abstract Details:

Poster Presentation:   
Date: May 4^th through May 6^th  
Time: 8:00 am
Location: Poster Presentation Section
Presenter: Dr. Aziz Nazha - Cleveland Clinic, Cleveland, Ohio  

A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in Myelodysplastic Syndromes (MDS) Patients Treated with Rigosertib versus Best Supportive Care (BSC) in a Randomized Controlled Phase III trial

Oral Presentation: 
Date: Saturday May 6^th
Time: 8:30 am-10 am
Location: Auditorium 1
Presenter:  Dr. Shyamala Navada - Mount Sinai School of Medicine, NYC 

Combination of Oral Rigosertib and Injectable Azacitidine In Patients with Myelodysplastic Syndromes (MDS)

Additional details and content from these presentations will be available on the Company's website on the day of the presentations. 

About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which blocks cellular signaling by targeting RAS effector pathways.  Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with Onconova's lead compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com.

GENERAL CONTACT: 
http://www.onconova.com/contact/
INVESTOR RELATIONS CONTACT: 
Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics
Lisa.Sher@mbsvalue.com / (212) 750-5800